{"DataElement":{"publicId":"7412717","version":"1","preferredName":"Transplant-Associated Thrombotic Microangiopathy Therapeutic Procedure Name","preferredDefinition":"The name of the treatment administered for transplant-associated thrombotic microangiopathy (TA-TMA).","longName":"PT_RCV_TX_AE_TP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7433881","version":"1","preferredName":"Transplant-Associated Thrombotic Microangiopathy Therapeutic Procedure","preferredDefinition":"Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"7433879v1.0:2554155v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7433879","version":"1","preferredName":"Transplant-Associated Thrombotic Microangiopathy","preferredDefinition":"Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections.","longName":"C174553","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplant-Associated Thrombotic Microangiopathy","conceptCode":"C174553","definition":"Thrombotic microangiopathy that presents in some patients undergoing hematopoietic stem cell transplantation (HSCT). Though similar in presentation to thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS), transplant-associated thrombotic microangiopathy (TA-TMA) is a distinct disorder. Several risk factors may be associated with TA-TMA, including high-dose chemotherapy, radiation therapy, HLA mismatch, use of calcineurin inhibitors, acute graft-versus-host disease (GVHD), and infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0016DB7-D2D0-2205-E053-4EBD850A7507","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"ONEDATA","dateModified":"2020-09-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2554155","version":"1","preferredName":"Therapeutic Procedure","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"249AD8D2-9892-0146-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-14","endDate":null,"createdBy":"UMLLOADER_TUMOR","dateCreated":"2006-12-14","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B0016DB7-D2DE-2205-E053-4EBD850A7507","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-23","modifiedBy":"FEIBUSHL","dateModified":"2021-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7412715","version":"1","preferredName":"Therapeutic Procedure Name","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The words or language units by which a thing is known.","longName":"7412715v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":"None","ValueMeaning":{"publicId":"4001711","version":"1","preferredName":"None","longName":"4001711","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED6DCE6B-B411-EF30-E040-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2013-12-13","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-12-13","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE722FE7-6CF9-29FE-E053-4EBD850AD8AD","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE722FE7-6D03-29FE-E053-4EBD850AD8AD","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"Steroids","valueDescription":"Steroid Compound","ValueMeaning":{"publicId":"4791933","version":"1","preferredName":"Steroid Compound","longName":"4791933","preferredDefinition":"A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Steroid Compound","conceptCode":"C843","definition":"Compounds possessing the skeleton of cyclopenta[a]phenanthrene or a skeleton derived therefrom by one or more bond scissions or ring expansions or contractions. Methyl groups are normally present at C-10 and C-13. An alkyl side chain may also be present at C-17.  They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"13B58EB7-C641-67FA-E050-BB89AD434046","latestVersionIndicator":"Yes","beginDate":"2015-04-14","endDate":null,"createdBy":"COLBERTM","dateCreated":"2015-04-14","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE722FE7-6D17-29FE-E053-4EBD850AD8AD","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"Plasmapheresis","valueDescription":"Plasmapheresis","ValueMeaning":{"publicId":"6159897","version":"1","preferredName":"Plasmapheresis","longName":"6159897","preferredDefinition":"The process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmapheresis","conceptCode":"C15304","definition":"A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A8BE-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE722FE7-6D21-29FE-E053-4EBD850AD8AD","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"Eculizumab","valueDescription":"Eculizumab","ValueMeaning":{"publicId":"7092697","version":"1","preferredName":"Eculizumab","longName":"7092697","preferredDefinition":"A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eculizumab","conceptCode":"C48386","definition":"A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D63FC7-EB45-7B51-E053-F662850A2C3A","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE722FE7-6D2B-29FE-E053-4EBD850AD8AD","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"ONEDATA","dateModified":"2020-09-03","deletedIndicator":"No"},{"value":"Defibrotide","valueDescription":null,"ValueMeaning":{"publicId":"10597959","version":"1","preferredName":"Defibrotide","longName":"10597959v1.00","preferredDefinition":"A mixture of single-stranded oligodeoxyribonucleotides derived from the intestinal mucosa of pigs, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Defibrotide","conceptCode":"C155981","definition":"A mixture of single-stranded oligodeoxyribonucleotides derived from the intestinal mucosa of pigs, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3C8E587-430A-653B-E053-731AD00AAEBC","latestVersionIndicator":"Yes","beginDate":"2022-07-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-14","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E3C8E587-430B-653B-E053-731AD00AAEBC","beginDate":"2022-07-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-07-14","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3629877","version":"1","preferredName":"Therapeutic Procedure Name","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:The words or language units by which a thing is known.","longName":"C49236:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CEF54A49-4A73-0AB2-E040-BB89AD431994","latestVersionIndicator":"Yes","beginDate":"2012-11-20","endDate":null,"createdBy":"KNUTSOND","dateCreated":"2012-11-20","modifiedBy":"ONEDATA","dateModified":"2012-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE722FE7-6CE3-29FE-E053-4EBD850AD8AD","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":"2021-03-12","createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"KUMMEROA","dateModified":"2022-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"If patient  has TA-TMA,what t","type":"Preferred Question Text","description":"If patient  has TA-TMA,what treatments have they received?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Which treatment/s did patient receive for TMA?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE723F00-32E4-0FD3-E053-4EBD850AC2E6","latestVersionIndicator":"Yes","beginDate":"2020-09-03","endDate":null,"createdBy":"STARGELM","dateCreated":"2020-09-03","modifiedBy":"BROWNTY","dateModified":"2022-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}